Adtec Microwave Argon Plasma has proven clinical efficacy in chronic infection management compared to standard care.

Adtec’s patented microwave argon plasma was designed specifically to create a denser safe plasma to manage infection with proven clinical efficacy over standard treatments. Our Plasma blend is effective at treating bacteria enclosed within biofilm and reaching hard to treat areas e.g. along drivelines. This clinical evidence has been presented at conferences and published in over 80 peer-reviewed publications.

 

The recent clinical evidence featured in Mr Thomas Schlöglhofer’s data illustrates the advantages of our SteriPlas medical device for deep LVAD infections. This showed Adtec Cold Plasma had 81% efficacy at wound management vs 47.1%  efficacy with standard of care.

 

“Cold Atmospheric Plasma Therapy as an Effective Treatment of Left Ventricular Assist Device Driveline Infections” at the EACTS European Association for Cardio-Thoracic Surgery conference in Vienna (October 2023) presented by Mr Thomas Schlöglhofer,  the Department of Cardiac Surgery, Medical University of Vienna.

 

Clinical Trials conducted using Adtec microwave argon plasma results include a 73.5% reduction in bacterial load with standard of care plus plasma treatment compared to a 50% reduction with standard of care alone. This represents a 47% increase in bacterial load reduction with SOC and plasma compared to SOC. All 24 patients received standard wound care to all wounds; 22 patients also received systemic antibiotics (92%).

Successful and Safe Use of 2 Min Cold Atmospheric Argon Plasma in Chronic Wounds: Results of A Randomized Controlled Trial. Isbary, G., et al British Journal of Dermatology, 2012. 167(2)


TFDA Approves SteriPlas in Taiwan

It is with great pleasure that we announce the SteriPlas Cold Plasma medical device is now an approved product in Taiwan, making it the first Cold Plasma medical device to be issued in the country. Adtec Healthcare Limited owes its thanks and praises to our exclusive distributor in Taiwan, SG Biomedical, whom without their skills in Regulatory and with the TFDA, none of this would have been possible.

The SteriPlas is already renowned in Taiwan for its strong clinical efficacy using premium and dense Cold Plasma and is set for distribution across the leading hospitals dealing with wound care. This is set to start within the coming months. If you are a health care professional in Taiwan that manages chronic wounds, we humbly request that you contact SG Biomedical who can guide you on the strong antibacterial benefits of the SteriPlas for diabetic foot ulcers, LVAD infections, sternal wounds and many more.

 

http://www.sghlds.com/index.php/tw/

 


SteriPlas Cold Plasma to be presented at EACTS 2023

 

We look forward to Mr Thomas Schlöglhofer’s presentation at the upcoming European Association for Cardio-Thoracic Surgery (EACTS) conference in Vienna on Fri 6th Oct. Thomas will present, “Cold Atmospheric Plasma Therapy as an Effective Treatment of Left Ventricular Assist Device Driveline Infections” which will feature the advantages of our SteriPlas Cold Plasma medical device for deep LVAD infections treated at the Department of Cardiac Surgery, Medical University of Vienna.

 

https://eacts2023.process.y-congress.com/ScientificProcess/schedule/?sessionGuid=b00559d1-4eff-4ca2-a20c-8d81ee71b8cf&setLng=en


Adtec presents at the LSI today

It was a pleasure to present at the LSI - Life Science Intelligence in Barcelona today. The successes of Adtec Healthcare Ltd and our Premium Cold Plasma medical device, the SteriPlas, were presented to the audience with much interest.

If you would like to know more about our strong clinical efficacy and antibiofilm properties for chronic wounds and infections, send us an email at info@adtecplasma.com


First day at the LSI

An epic start to the first day at LSI - Life Science Intelligence in Barcelona.

It has been a pleasure to interact with professionals sharing the same interest in tackling strains on the global wound care market. The benefits that the clinically proven SteriPlas can bring to significantly reduce bed occupancy, chronic infections and the financial burden rates have been demonstrated.

We look forward to presenting more about this on the 21st Sept and encourage you to meet with us whilst at LSI to learn more about our Premium Cold Plasma medical device for chronic wounds, surgical site infections and medical dermatology conditions.


Life Science Intelligence Conference in Barcelona

Adtec Healthcare Ltd will be presenting at the Life Science Intelligence (LSI) Barcelona from 18-22 September 2023. Our Managing Director, Mary, will be showcasing the successes Adtec Healthcare and the SteriPlas have brought to clinical practices dealing with non-healing chronic wounds burdened with biofilm. Mary’s presentation will be held at 10:35 - 10:44 on September 21st and we encourage you to attend and ask your questions to better learn why we remain the leader of high density Cold Plasma medicine.


Advanced Wound Care Summit 2023

We hope you got to see our presentation at the Advanced Wound Care Summit yesterday. We thoroughly enjoyed explaining the strong benefits of our SteriPlas Cold Plasma for biofilm destruction. If you would like to learn more about our medical device and clinical evidence, send us an email info@adtecplasma.com


Size Does Matter!

Size does matter!

Yes, we do manufacture smaller handheld Cold Plasma devices that have antibacterial efficacy but we do not sell these in the medical field. A quick 2 minute treatment time is respective of being focused on the size of the plasma area created. Small and handheld plasma jet devices feature a 1mm2 treatment area which means antibacterial efficacy is achieved in a very small area for every 2 minutes applied. If the wound is 10cm2, we will leave you to do the maths on how long it will take to treat! This is why we do not sell handheld plasma jet pens as medical devices as they are limited to small and superficial wounds.

 

The SteriPlas creates a gigantic 12cm2 treatment area which is only possible through the size of the medical device which incorporates a series of crucial components such as the generator and control unit. This means the SteriPlas can cover large wounds and finish treatment in as quick as a single two minute session. Whilst the SteriPlas can treat acute and superficial wounds, it is designed to target deep and complicated wounds with #biofilm.

Deep sternal wounds is a classic example as documented in our clinical evidence. 

 


Leading Cold Plasma medicine with the SteriPlas

 

The SteriPlas produces a repeatable, reliable, and highly efficacious Cold Plasma that has been proven in clinical trials and studies to destroy bacteria protected deep within biofilm.

 

Regardless of the resistance profile of bacteria, whether they are Gram-negative or Gram-positive, the physical mode of action of the SteriPlas Cold Plasma ensures the destruction of bacteria at the site of infection. This is particularly beneficial for difficult-to-treat or non-healing wounds such as diabetic foot ulcers, sternal wounds and LVAD infections. Where biofilm typically complicates the treatment options for these infections, the SteriPlas has been shown to fully heal patients even if they were not responding to antibiotic treatment to begin with thus saving limbs and lives.

 

All of this is achieved with the reputable safety of SteriPlas with no side effects reported.


The Leader of Cold Plasma

There is expanding interest of our medical device for the treatment of chronic diabetic foot ulcers, deep sternal wounds and LVAD infections. We wish to remind you that if you are a Health Care Professional seeking to learn more about our medical device then please do get in contact with us. A member of our team will be able to show the full benefits and safety of using our medical device to treat these complicated conditions, with no side effects.

 

As Adtec Healthcare remains the leader of cold plasma medicine, we are lucky to be able to boast a wide clinical bibliography collection that really makes us stand out amongst the rest. We were the first company worldwide to do clinical trials of cold plasma on chronic wounds.  Our clinical trials data has paved way in today’s medicine to show cold plasma as the go-to alternative for infection management.

 

If you are interested to bring the benefits of cold plasma to your patients, please email us at info@adtecplasma.com